1st Counsel – Lifestyle
Author:
Skyhawk Therapeutics
Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society’s 2026 Medal of Honor
March 30, 2026
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington’s Disease
March 10, 2026
FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%
March 10, 2026